Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition

Cancer Gene Therapy

Volumn 21, Issue 9, 2014, Pages 381-388

  Warrier, S ^a,b   Bhuvanalakshmi, G ^a   Arfuso, F ^b,c   Rajan, G ^c   Millward, M ^d   Dharmarajan, A ^b  

^a Manipal Academy of Higher Education   (India)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CD24 ANTIGEN; CISPLATIN; DOXORUBICIN; HERMES ANTIGEN; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; NERVE CELL ADHESION MOLECULE; SECRETED FRIZZLED RELATED PROTEIN 4; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; WNT3A PROTEIN; MEMBRANE ANTIGEN; ONCOPROTEIN; SFRP4 PROTEIN, HUMAN; WNT PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEP 2 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KB CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; REAL TIME POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEAD AND NECK TUMOR; IMMUNOPHENOTYPING; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

GASTROPODA;

ANTIGENS, SURFACE; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84927001056     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.42     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
5. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978.
6. Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev 2012; 38: 515-539.
7. Lim YC, Kang HJ, Kim-S, Choi EC. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/?-catenin pathway. Eur J Cancer 2012; 48: 3310-3318.
8. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res 2006; 66: 4549-4552.
9. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
10. Song J, Chang I, Chen Z, Kang M, Wang CY. Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One 2010; 5: e11456.
11. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287-4295.
12. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferonalpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100: 1647-1658.
13. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009; 28: 2245-2256.
14. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. C-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta catenin-ATP-binding cassette G2 signaling. Oncogene 2013; 32: 2767-2781.
15. Warrier S, Balu SK, Kumar AP, Millward M, Dharmarajan A. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res 2014; 21: 93-102.
16. Warrier S, Pavanram P, Raina D, Arvind M. Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int 2012; 36: 137-143.
17. Haegebarth A, Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am J Pathol 2009; 174: 715-721.
18. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/betacatenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 32: 1650-1653.
19. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28: 5-16.
20. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28: 17-28.
21. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P et al. Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008; 14: 238-249.
22. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009; 4: 559-567.
23. Kawano Y, Kypta RJ. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627-2634.
24. You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A et al. Inhibition of Wnt-1 signaling induces apoptosis in ?-catenin-deficient mesothelioma cells. Cancer Res 2004; 64: 3474-3478.
25. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N et al. Dickkopf-1 antagonizes Wnt signaling independent of ?-catenin in human mesothelioma. Biochem Biophys Res Commun 2004; 323: 1246-1250.
26. Guo K, Wolf V, Dharmarajan AM, Feng Z, Bielke W, Saurer S et al. Apoptosisassociated gene expression in the corpus luteum of the rat. Biol Reprod 1998; 58: 739-746.
27. Lacher MD, Siegenthaler A, Jaeger R, Yan X, Hett S, Xuan L et al. Role of DDC-4/sFRP, a secreted frizzled-related protein, in the onset of apoptosis in mammary involution. Cell Death Differ 2003; 10: 528-538.
28. Feng Han Q, Zhao W, Bentel J, Shearwood AM, Zeps N, Joseph D et al. Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett 2006; 231: 129-137.
29. Hewitt DP, Mark PJ, Dharmarajan AM, Waddell BJ. Placental expression of secreted frizzled related protein-4 in rat and the impact of glucocorticoid-induced fetal and placental growth restriction. Biol Reprod 2006; 75: 75-81.
30. Kaler P, Godasi BN, Augenlicht L, Klampfer L. The NF-kappaB/AKT-dependent Induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron 2009; 2: 69-80.
31. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One 2013; 8: e67811.
32. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004; 25: 641-649.
33. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signaling. Gut 2009; 58: 949-963.
34. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757.
35. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
36. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
37. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
38. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
39. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26: 1357-1360.
40. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-513.
41. Lim YC, Oh SY, Kim SH, Jin X, Kim H. Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol 2011; 47: 83-91.